Jianfei Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jianfei Wang has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Jian Li
WuXi AppTec , 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, P. R. China
1 shared publicationLiang Shen
WuXi AppTec , 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, P. R. China
1 shared publication- Lu Yang
Department of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong
1 shared publication Shaohua Li
WuXi AppTec , 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, P. R. China
1 shared publicationShuhui Chen
WuXi AppTec , 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, P. R. China
1 shared publication- Shuqing Ma
National University of Defense Technology
1 shared publication
Latest Publications
- Open Access
- 2 May 2023
- Published by Elsevier in Ocean Engineering
- Vol. 280, 114656
Research on the broadband source localization of a vector hydrophone vertical line array in the deep sea
- 2 May 2023
- Published by Elsevier in Ocean Engineering
- Vol. 280, 114656
Open AccessResearch on the broadband source localization of a vector hydrophone vertical line array in the deep sea
- 16 February 2017
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 8 (3) , 299-303
Discovery and Assessment of Atropisomers of (±)-Lesinurad
(+)- and (−)-Lesinurad were isolated as atropisomers from racemic lesinurad for the first time. No interconversion was observed between the two atropisomers under various conditions tested. The two atropisomers showed significant differences in hURAT1 highly expressed HEK293 cell-based inhibition assays, monkey pharmacokinetic studies, and in vitro human recombinant CYP2C9 stability studies. It was speculated that (+)-lesinurad might offer a better hyperuricemia/gout therapy than (−)-lesinurad or the racemate.
- 16 February 2017
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 8 (3) , 299-303
Discovery and Assessment of Atropisomers of (±)-Lesinurad
(+)- and (−)-Lesinurad were isolated as atropisomers from racemic lesinurad for the first time. No interconversion was observed between the two atropisomers under various conditions tested. The two atropisomers showed significant differences in hURAT1 highly expressed HEK293 cell-based inhibition assays, monkey pharmacokinetic studies, and in vitro human recombinant CYP2C9 stability studies. It was speculated that (+)-lesinurad might offer a better hyperuricemia/gout therapy than (−)-lesinurad or the racemate.